LifeNet Health has announced the launch of OraGen, the first viable dental bone allograft comprised of cryopreserved corticocancellous bone containing endogenous lineage-committed bone cells combined with demineralised bone matrix. The composition, which forms the core of OraGen’s innovation, delivers three essential properties for bone regeneration: osteogenicity, with lineage-committed bone cells that produce new bone; osteoconductivity, providing a biocompatible scaffold for cell attachment and growth; and osteoinduction, which stimulates bone repair through retained natural growth factors.
OraGen is designed for use in dental procedures, including sinus and ridge augmentation and repairing large defects in the mandible or maxilla. Building on the proven clinical success of LifeNet Health’s advanced cellular allografts in bone repair and reconstruction, OraGen seeks to deliver a transformative and innovative approach in dental tissue engineering, ushering in a new era of innovation and effectiveness in bone regeneration.1 It enables rapid new bone formation immediately after implantation and sustained growth over time.2-4
OraGen also delivers safety and convenience. It has undergone aseptic processing and features a cryopreservation method that maximises cell viability by processing grafts within 72 hours — 24 hours faster than competing products. OraGen also thaws in under five minutes, ensuring quick and easy preparation in clinical settings.
OraGen is now available in the US through LifeNet Health’s strategic partner, Salvin Dental Specialties.
“We are thrilled to collaborate with Salvin Dental Specialties to introduce OraGen to the market,” said Daniel Osborne, chief growth officer at LifeNet Health. “This partnership reflects our commitment to delivering cutting-edge solutions that not only drive better patient outcomes but also advance the field of regenerative medicine. Together, we’re not just facilitating healing; we’re improving lives.”
“Salvin Dental’s exclusive distribution agreement with LifeNet Health for OraGen demonstrates our unwavering commitment to providing the most comprehensive and innovative regenerative solutions to our customers,” added Ken Serota, CEO of Young Innovations. “Salvin’s enduring partnership with LifeNet Health has consistently focused on enhancing patient outcomes through a dedication to quality and service. Together, we look forward to empowering dental surgeons to improve their patients’ quality of life.”
LifeNet Health and Salvin Dental Specialties are committed to delivering these advancements with unmatched quality and exceptional customer support, strengthening their shared mission to elevate the standard of care in dental surgery.
